IDH1 and central nervous system cancer: Gliomas with mutations in IDH (isocitrate dehydrogenase), which leads to loss of its normal enzymatic function and the abnormal production of oncometabolite 2-hydroxyglutarate, represent a unique subset genetically and clinically distinct from that carrying wild-type IDH, particularly in LGG [27].